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BACKGROUND
Obesity is a chronic disease with serious health consequences, but weight loss is 
difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-
like peptide-1 analogue, has been shown to have potential benefit for weight 
management at a once-daily dose of 3.0 mg, injected subcutaneously.
METHODS
We conducted a 56-week, double-blind trial involving 3731 patients who did not 
have type 2 diabetes and who had a body-mass index (BMI; the weight in kilo-
grams divided by the square of the height in meters) of at least 30 or a BMI of at 
least 27 if they had treated or untreated dyslipidemia or hypertension. We ran-
domly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections 
of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both 
groups received counseling on lifestyle modification. The coprimary end points were 
the change in body weight and the proportions of patients losing at least 5% and 
more than 10% of their initial body weight.
RESULTS
At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean 
weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of 
the patients were women and 61.2% had prediabetes. At week 56, patients in the 
liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the 
placebo group had lost a mean of 2.8±6.5 kg (a difference of −5.6 kg; 95% confi-
dence interval, −6.0 to −5.1; P<0.001, with last-observation-carried-forward impu-
tation). A total of 63.2% of the patients in the liraglutide group as compared with 
27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 
33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). 
The most frequently reported adverse events with liraglutide were mild or moder-
ate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the 
liraglutide group and in 5.0% of the patients in the placebo group.
CONCLUSIONS
In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associ-
ated with reduced body weight and improved metabolic control. (Funded by Novo 
Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, 
NCT01272219.)
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The increase in the rate of obesity, a chronic disease with serious health con-sequences, largely explains the recent tri-
pling in the prevalence of type 2 diabetes.1,2 
Weight loss of 5 to 10% has been shown to re-
duce complications related to obesity and im-
prove quality of life3-7; however, weight loss is 
difficult to maintain with lifestyle intervention 
alone.8
Liraglutide, a glucagon-like peptide-1 analogue 
with 97% homology to human glucagon-like 
peptide-1, is approved for the treatment of type 2 
diabetes at doses up to 1.8 mg once daily.9 Weight 
loss with liraglutide is dose-dependent up to 3.0 mg 
once daily10,11 and is mediated by reduced appe-
tite and energy intake rather than by increased 
energy expenditure.12
This 56-week, randomized, placebo-controlled 
trial aimed to evaluate the efficacy and safety of 
3.0 mg of liraglutide, injected subcutaneously 
once daily, as an adjunct to a reduced-calorie 
diet and increased physical activity, for weight 
management in overweight or obese adults who 
did not have diabetes at baseline.
Me thods
Study Overview
We conducted the study from June 1, 2011, 
through March 18, 2013, at 191 sites in 27 coun-
tries in Europe, North America, South America, 
Asia, Africa, and Australia. The trial protocol 
was approved by local ethics committees or in-
stitutional review boards and is available with 
the full text of this article at NEJM.org. The trial 
was conducted in accordance with the principles 
of the Declaration of Helsinki13 and Good 
Clinical Practice guidelines.14 A 2-year exten-
sion of the trial involving patients with predia-
betes that was designed to evaluate whether lira-
glutide is associated with delayed onset of type 2 
diabetes was recently completed. All the au-
thors were involved in the design or conduct of 
the study and the preparation of the manu-
script, including the decision to submit it for 
publication, and all attest to the accuracy and 
completeness of data and the data analyses. 
The sponsor, Novo Nordisk, planned and per-
formed the statistical analyses, provided editorial 
and writing assistance, and provided the trial 
drugs.
Patients
The trial enrolled patients 18 years of age or 
older who had stable body weight and a body-
mass index (BMI; the weight in kilograms di-
vided by the square of the height in meters) of 
30 or higher, or 27 or higher if the patient had 
treated or untreated dyslipidemia or hyperten-
sion (Table S1 in the Supplementary Appendix, 
available at NEJM.org). All the patients provided 
written informed consent before participation. 
Key exclusion criteria were type 1 or 2 diabetes, 
the use of medications that cause clinically sig-
nificant weight gain or loss, previous bariatric 
surgery, a history of pancreatitis, a history of 
major depressive or other severe psychiatric dis-
orders, and a family or personal history of mul-
tiple endocrine neoplasia type 2 or familial 
medullary thyroid carcinoma. Details of the eli-
gibility and exclusion criteria are provided in the 
Supplementary Appendix.
Study Design and Treatments
Randomization was performed with the use of 
a telephone or Web-based system provided by 
the sponsor. Eligible patients were randomly as-
signed, in a 2:1 ratio, to receive once-daily sub-
cutaneous injections of liraglutide, starting at a 
dose of 0.6 mg with weekly 0.6-mg increments 
to 3.0 mg, or placebo; both groups received 
counseling on lifestyle modification (Fig. S1 in 
the Supplementary Appendix). Patients were 
stratified according to prediabetes status at 
screening15 and according to BMI (≥30 vs. <30). 
Patients, investigators, and the sponsor were 
unaware of the study-group assignments. Lira-
glutide and placebo were provided in FlexPen 
devices (Novo Nordisk). After 56 weeks, patients 
in the liraglutide group who did not have pre-
diabetes at screening were randomly assigned 
in a 1:1 ratio to continue receiving liraglutide or 
to switch to placebo for 12 weeks to assess 
whether efficacy was maintained after discontin-
uation of liraglutide treatment and whether there 
were safety issues related to discontinuation. Pa-
tients in the placebo group continued to receive 
placebo.
Study Procedures and End Points
Patients were evaluated every 2 weeks until 
week 8; thereafter, patients were evaluated every 
4 weeks until week 44 and were evaluated again 
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at weeks 50, 56, 58, 60, 64, 68, and 70. All pa-
tients received standardized counseling on life-
style modification approximately monthly (see 
the Supplementary Appendix).11 Patients who with-
drew early were asked to return at week 56 for 
measurement of their weight and recording of 
adverse events.
The three prespecified coprimary end points, 
assessed at week 56, were weight change from 
baseline, the proportion of patients who lost at 
least 5% of their baseline body weight, and the 
proportion of patients who lost more than 10% 
of their baseline body weight. Secondary end 
points included changes from baseline in BMI, 
waist circumference, glycemic control variables, 
cardiometabolic biomarkers, and health-related 
quality of life. The timing of assessments is de-
scribed in the Methods section in the Supple-
mentary Appendix. Health-related quality of life 
was assessed with the use of the Medical Out-
comes Study 36-Item Short-Form Health Survey 
(SF-36; in which higher scores indicate better 
quality of life)16 and the Impact of Weight on 
Quality of Life–Lite17 (in which higher scores 
indicate better quality of life) and Treatment Re-
lated Impact Measure–Weight18 (in which higher 
scores indicate better quality of life) question-
naires. The proportion of patients who modified 
their use of lipid-lowering or antihypertensive 
medications was also assessed. Additional meth-
ods are described in the Supplementary Appendix.
Specific attention was given to types of ad-
verse events that have an increased prevalence 
among obese persons or that were relevant to 
the drug class of liraglutide: of 17 types of ad-
verse events, 9 were prospectively assessed by 
independent medical experts who were unaware 
of the study-group assignments (Table S2 in the 
Supplementary Appendix). We report adverse 
events that occurred during the main 56-week 
trial period, with onset on or after the first day 
of treatment and no later than 14 days after the 
last day of treatment, unless otherwise stated.
Statistical Analysis
We estimated that with a sample size of 2400 
patients assigned to receive liraglutide and 1200 
assigned to receive placebo, the study would 
have more than 99% power to detect a between-
group difference in the three coprimary efficacy 
end points of the main 56-week trial and in the 
primary end point of the 2-year extension. The 
power for the first coprimary end point, weight 
change, was calculated with the use of a two-
sided Student’s t-test at a 5% significance level. 
The power for the two categorical coprimary end 
points was calculated with the use of a two-
sided chi-square test, also at a 5% significance 
level (see the Supplementary Appendix).
The prespecified efficacy analyses used data 
from the full-analysis set, which included all 
patients who underwent randomization and re-
ceived at least one dose of a study drug and had 
at least one assessment after baseline. The safety-
analysis set included all patients who were ran-
domly assigned to a study group and had exposure 
to a study drug. Missing values were imputed with 
the use of the last-observation-carried-forward 
method for measurements made after baseline. 
For weight, only fasting measurements were 
used. The three coprimary end points were ana-
lyzed in hierarchical order. An analysis of covari-
ance model was used to analyze mean changes 
in continuous end points. The model included 
treatment, country, sex, BMI stratification, status 
with respect to prediabetes at screening, and 
interaction between BMI strata and prediabetes 
status as fixed effects, with the baseline value of 
the relevant variable as a covariate. Categorical 
changes for dichotomous end points were ana-
lyzed with the use of logistic regression with the 
same fixed effects and covariates as the respective 
analysis of covariance. Sensitivity analyses, per-
formed to assess the robustness of the primary 
analyses, included repeated-measures and multi-
ple-imputation analyses, which used a model-
based approach for missing data (see the Supple-
mentary Appendix). A total of 63 prespecified 
subgroup analyses were performed to investigate 
whether prediabetes status had any effect on 
the primary and secondary end points and wheth-
er baseline BMI (in four categories) had any 
effect on weight or glycated hemoglobin level 
(see the Methods in the Supplementary Appen-
dix). Results are presented only if an effect was 
shown.
R esult s
Trial Population
A total of 3731 patients underwent randomiza-
tion: 2487 to lifestyle intervention plus liraglu-
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tide, at a dose of 3.0 mg once daily, and 1244 to 
lifestyle intervention plus placebo. The baseline 
characteristics were similar in the two groups 
(Table 1, and Tables S3 and S4 in the Supple-
mentary Appendix). A total of 1789 patients 
(71.9%) in the liraglutide group, as compared 
with 801 patients (64.4%) in the placebo group, 
completed 56 weeks of treatment (Fig. S2 in the 
Supplementary Appendix). A larger percentage 
of patients in the liraglutide group than in the 
placebo group withdrew from the trial owing to 
adverse events (9.9% [246 of 2487 patients] vs. 
3.8% [47 of 1244]); a smaller percentage of pa-
tients in the liraglutide group withdrew from 
the trial owing to ineffective therapy (0.9% [23 
of 2487] vs. 2.9% [36 of 1244]) or withdrew 
their consent (10.6% [264 of 2487] vs. 20.0% 
[249 of 1244]).
Body Weight
After 56 weeks, patients in the liraglutide group 
had lost a mean (±SD) of 8.0±6.7% (8.4±7.3 kg) 
of their body weight, whereas patients in the 
placebo group had lost a mean of 2.6±5.7% 
(2.8±6.5 kg) of their body weight (Table 2). 
Weight loss with liraglutide was maintained over 
56 weeks and was similar regardless of pre-
diabetes status (Fig. 1A). A greater proportion 
of patients in the liraglutide group than in the 
placebo group lost at least 5% of their body 
weight (63.2% vs. 27.1%), more than 10% of 
their body weight (33.1% vs. 10.6%), and more 
than 15% of their body weight (14.4% vs. 3.5%) 
(Fig. 1B). Overall, approximately 92% of the 
patients in the liraglutide group and approxi-
mately 65% of the patients in the placebo 
group lost weight (Fig. 1C). The liraglutide group 
also had a greater reduction than the placebo 
group in mean waist circumference and BMI 
(Table 2).
Several sensitivity analyses confirmed the su-
periority of liraglutide over placebo with respect 
to the coprimary end points (Table S6 in the 
Supplementary Appendix). Liraglutide appeared 
to be less effective in patients with a mean BMI 
of 40 or higher than in patients with a lower 
BMI (Fig. S4 in the Supplementary Appendix). 
Estimated mean changes in body weight and 
secondary end points are presented in Tables S6 
and S8 in the Supplementary Appendix.
Glycemic Control
There was a greater reduction in glycated hemo-
globin, fasting glucose, and fasting insulin levels 
in the liraglutide group than in the placebo 
group (Table 2). Liraglutide was also associated 
with a lowering of plasma glucose levels (Fig. 2A) 
and higher insulin and C-peptide levels relative 
to placebo during an oral glucose-tolerance test 
(Fig. S3 in the Supplementary Appendix). The 
effects of liraglutide on glycated hemoglobin, 
fasting glucose, and glucose levels during the 
oral glucose-tolerance test were greater in pa-
tients with prediabetes than in those without 
(P<0.001) (Table S9 in the Supplementary Ap-
pendix). Measures of insulin resistance and beta-
cell function also showed improvement with 
liraglutide as compared with placebo (Table S10 
in the Supplementary Appendix).
The prevalence of prediabetes was signifi-
cantly lower in the liraglutide group than in the 
placebo group at week 56 (Fig. 2B), a finding 
that was consistent with the improvement in 
glycemic control with liraglutide. Type 2 diabe-
tes developed in more patients in the placebo 
group than in the liraglutide group during the 
course of treatment.
Cardiometabolic Variables
Systolic and diastolic blood pressure decreased 
more in the liraglutide group than in the placebo 
group by week 56 (Table 2). All measures of fast-
ing lipid levels (Table 2), as well as levels of high-
sensitivity C-reactive protein, plasminogen acti-
vator inhibitor-1, and adiponectin (Table S8 in 
the Supplementary Appendix), showed greater 
improvement in the liraglutide group than in the 
placebo group.
Health-Related Quality of Life
Liraglutide treatment was associated with higher 
scores on the SF-36 for overall physical and men-
tal health, a higher total score (indicating better 
quality of life) on the Impact of Weight on Qual-
ity of Life–Lite questionnaire (Table S7 in the 
Supplementary Appendix), and more favorable 
individual domain scores on both instruments 
(Fig. S5 in the Supplementary Appendix) than 
was placebo. The total score and the scores for 
weight management and treatment burden on 
the Treatment Related Impact Measure–Weight 
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Characteristic Liraglutide (N = 2487) Placebo (N = 1244)
Sex — no. (%)
Female 1957 (78.7) 971 (78.1)
Male 530 (21.3) 273 (21.9)
Age — yr 45.2±12.1 45.0±12.0
Race or ethnic group — no. (%)†
White 2107 (84.7) 1061 (85.3)
Black 242 (9.7) 114 (9.2)
Asian 90 (3.6) 46 (3.7)
American Indian or Alaska Native 5 (0.2) 4 (0.3)
Native Hawaiian or other Pacific Islander 2 (<0.1) 2 (0.2)
Other 41 (1.6) 17 (1.4)
Hispanic or Latino ethnic group† 259 (10.4) 134 (10.8)
Weight — kg 106.2±21.2 106.2±21.7
Body-mass index‡ 38.3±6.4 38.3±6.3
Body-mass index categories — no. (%)‡
27–29.9: overweight 66 (2.7) 44 (3.5)
30–34.9: obese class I 806 (32.4) 388 (31.2)
35–39.9: obese class II 787 (31.6) 398 (32.0)
≥40: obese class III 828 (33.3) 414 (33.3)
Waist circumference — cm 115.0±14.4 114.5±14.3
Glycated hemoglobin — % 5.6±0.4 5.6±0.4
Fasting glucose — mg/dl 95.9±10.6 95.5±9.8
Fasting insulin — μIU/ml§ 16.3±79.8 16.1±89.3
Blood pressure — mm Hg
Systolic 123.0±12.9 123.2±12.8
Diastolic 78.7±8.6 78.9±8.5
Cholesterol — mg/dl
Total 193.7±19.1 194.3±18.8
LDL 111.6±27.9 112.2±27.6
HDL 51.4±26.2 51.0±26.4
VLDL 25.1±49.6 25.7±49.4
Free fatty acids — mmol/liter 0.45±40.5 0.46±39.7
Triglycerides — mg/dl 126.2±56.9 128.9±61.0
Prediabetes — no. (%)¶ 1528 (61.4) 757 (60.9)
Dyslipidemia — no. (%)‖ 737 (29.6) 359 (28.9)
Hypertension — no. (%)‖ 850 (34.2) 446 (35.9)
*  Plus–minus values are observed means ±SD. For fasting insulin and lipid levels, plus–minus values are geometric means 
and coefficients of variation. There were no statistically significant differences between the two groups for any charac-
teristic. To convert values for glucose to millimoles per liter, multiply by 0.05551. To convert values for cholesterol to 
millimoles per liter, multiply by 0.0259. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and VLDL 
very-low-density lipoprotein.
†  Race and ethnic group were self-reported. Patients from France did not report race or ethnic group.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  The reference range is 3.0 to 25.0 μIU/mL for both sexes and all ages.
¶  Prediabetes was defined according to American Diabetes Association 2010 criteria.15
‖  The diagnoses of dyslipidemia and hypertension were based on self-reported medical history.
Table 1. Baseline Characteristics of the Patients.*
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questionnaire were also higher in the liraglutide 
group than in the placebo group, although the 
liraglutide group had a lower score for the expe-
rience of side effects.
Side Effects and Adverse Events
Among patients in the safety-analysis set, the 
most common side effects in the liraglutide 
group were related to the gastrointestinal system 
End Point
Liraglutide  
(N = 2437)
Placebo 
(N = 1225)
Estimated Treatment 
Difference, Liraglutide 
vs. Placebo (95% CI)† P Value
Coprimary end points
Change in body weight
% of body weight −8.0±6.7 −2.6±5.7 −5.4 (−5.8 to −5.0) <0.001
Kilograms of body weight −8.4±7.3 −2.8±6.5 −5.6 (−6.0 to −5.1) <0.001
Loss of ≥5% body weight (%)‡ 63.2 27.1 4.8 (4.1 to 5.6) <0.001
Loss of >10% body weight (%)‡ 33.1 10.6 4.3 (3.5 to 5.3) <0.001
Body weight-related end points
Body-mass index −3.0±2.6 −1.0±2.3 −2.0 (−2.2 to −1.9) <0.001
Waist circumference (cm) −8.2±7.3 −3.9±6.6 −4.2 (−4.7 to −3.7) <0.001
Glycemic control variables
Glycated hemoglobin (%) −0.30±0.28 −0.06±0.30 −0.23 (−0.25 to −0.21) <0.001
Fasting glucose (mg/dl) −7.1±10.8 0.1±10.4 −6.9 (−7.5 to −6.3) <0.001
Fasting insulin (%) −12.6 −4.4 −8 (−12 to −5) <0.001
Fasting C-peptide (%) −8.9 −7.9 −1 (−3 to 2) 0.51
Vital signs
Systolic blood pressure (mm Hg) −4.2±12.2 −1.5±12.4 −2.8 (−3.56 to −2.09) <0.001
Diastolic blood pressure (mm Hg) −2.6±8.7 −1.9±8.7 −0.9 (−1.41 to −0.37) <0.001
Pulse (beats/min) 2.5±9.8 0.1±9.5 2.4 (1.9 to 3.0) <0.001
Fasting lipid profile
Cholesterol (%)
Total −3.1 −1.0 −2.3 (−3.3 to −1.3) <0.001
LDL −3.0 −1.0 −2.4 (−4.0 to −0.9) 0.002
HDL 2.3 0.7 1.9 (0.7 to 3.0) 0.001
VLDL −13.1 −5.5 −9.1 (−11.4 to −6.8) <0.001
Non-HDL −5.1 −1.8 −3.9 (−5.2 to −2.5) <0.001
Triglycerides −13.3 −5.5 −9.3 (−11.5 to −7.0) <0.001
Free fatty acids 1.7 3.5 −4.2 (−7.3 to −0.9) 0.01
*  Plus–minus values are observed means ±SD. For fasting insulin, fasting C-peptide, and fasting lipids, the relative change 
from baseline is presented. Post hoc analysis was performed for non-HDL cholesterol.
†  Estimated treatment differences are from an analysis of covariance with data from the full-analysis set, with last-obser-
vation-carried-forward (LOCF) imputation. The full-analysis set comprised patients who underwent randomization, were 
exposed to at least one treatment dose, and had at least one assessment after baseline (69 patients were excluded 
from the full-analysis set: 61 owing to lack of an assessment and 8 owing to no exposure). Data on pulse are based on 
the safety-analysis set, which included all patients who were randomly assigned to a study group and had exposure to a 
study drug. Data for fasting insulin, fasting C-peptide, and fasting lipids were log-transformed for analysis and are pre-
sented as relative treatment differences.
‡  Loss of at least 5% and more than 10% of body weight were analyzed by logistic regression with data from the full-analysis 
set, with LOCF imputation, and are presented as the proportions of patients (%) and odds ratios.
Table 2. Changes in Coprimary End Points and Cardiometabolic Risk Factors between Baseline and Week 56.*
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(Table 3); 94% or more were of mild or moderate 
severity. Gastrointestinal events were also the 
most common reason that patients in the lira-
glutide group withdrew from the trial (159 of 
2481 patients [6.4%], as compared with 9 of 1242 
patients [0.7%] in the placebo group) (Fig. S6 in 
the Supplementary Appendix). Nausea (Fig. S7 in 
the Supplementary Appendix) and vomiting oc-
curred primarily within the first 4 to 8 weeks 
after initiation of liraglutide treatment. The inci-
dence of serious adverse events was higher in the 
liraglutide group than in the placebo group 
(Table 3). Three patients died — 1 in the liraglu-
tide group (with death due to cardiomegaly and 
hypertensive heart disease) and 2 in the placebo 
group (one death each from pulmonary fibrosis 
and cardiorespiratory arrest).
Gallbladder-related events were more com-
mon in the liraglutide group than in the pla-
cebo group (occurring in 61 of 2481 patients 
[2.5%], 3.1 events per 100 patient-years of expo-
sure; vs. 12 of 1242 patients [1.0%], 1.4 events 
per 100 patient-years of exposure), including more 
cases of cholelithiasis and cholecystitis in the 
liraglutide group. Most patients who reported 
cholelithiasis or cholecystitis underwent an elec-
tive cholecystectomy (40 of 51 patients [78%] in 
the liraglutide group and 6 of 8 patients [75%] 
in the placebo group), and most recovered and 
continued their assigned course of treatment or 
had treatment reintroduced after surgery (43 of 
51 patients [84%] in the liraglutide group and 
6 of 8 patients [75%] in the placebo group). The 
weight loss among patients with gallbladder-
related adverse events was greater than the mean 
weight loss in the total population (Fig. S8 in the 
Supplementary Appendix).
Figure 1. Liraglutide and Body Weight.
Panel A shows the mean body weight for patients in 
the full-analysis set who completed each scheduled 
visit, according to presence or absence of prediabetes 
at screening. I bars indicate standard error, and the 
separate symbols above the curves represent the 56-
week weight change using last-observation-carried- 
forward (LOCF) imputation. The full-analysis set com-
prised patients who underwent randomization, were 
exposed to at least one treatment dose, and had at 
least one assessment after baseline (69 patients were 
excluded from the full-analysis set: 61 owing to lack of 
an assessment and 8 owing to no exposure). Panel B 
shows the proportions of patients who lost at least 5%, 
more than 10%, and more than 15% of their baseline 
body weight. Data shown are the observed means for 
the full-analysis set (with LOCF). Findings from logis-
tic-regression analysis showed an odds ratio of 4.8 
(95% confidence interval [CI], 4.1 to 5.6) for at least 
5% weight loss and an odds ratio of 4.3 (95% CI, 3.5  
to 5.3) for more than 10% weight loss; the analysis of 
more than 15% weight loss was performed post hoc 
(odds ratio, 4.9 [95% CI, 3.5 to 6.7]). Panel C shows the 
cumulative percentage of patients with those changes 
in body weight after 56 weeks of treatment.
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The rates of adverse events of pancreatitis 
(Table S11 in the Supplementary Appendix) and 
neoplasms were calculated in terms of 100 patient-
years at risk, covering the period from the start 
of treatment until the final contact with the 
patient (including events that occurred during 
the second randomized period after the end of 
the 56-week main study and those that occurred 
15 days or more after the last day the study drug 
was received). Overall, 11 cases of pancreatitis 
were confirmed by adjudication; these cases oc-
curred in 10 of 2481 patients in the liraglutide 
Figure 2. Liraglutide and Glucose Levels during Oral Glucose-Tolerance Test and Glycemic Status.
Panel A shows the mean plasma glucose levels during a 75-g oral glucose-tolerance test (OGTT), according to prediabetes status at 
screening in the full-analysis set. The OGTT was performed at screening for the diagnosis of prediabetes and again after 56 weeks of 
 assigned treatment (see the Methods section in the Supplementary Appendix). To convert the values for glucose to millimoles per liter, 
multiply by 0.05551. Panel B shows the prediabetes status after 56 weeks in patients who had normoglycemia and in those who had pre-
diabetes at screening. Findings from logistic-regression analysis showed an odds ratio for prediabetes at week 56 of 3.3 (95% confidence 
interval [CI], 2.4 to 4.7) among patients with normoglycemia at screening and 4.9 (95% CI, 4.0 to 5.9) among patients with prediabetes 
at screening. In Panels A and B, data shown are the observed means for the full-analysis set (with last-observation-carried-forward imputa-
tion). Panel C shows Kaplan-Meier estimates of the proportion of patients who received a diagnosis of type 2 diabetes during the course 
of the 56-week main trial period. Findings from logistic-regression analysis showed an odds ratio for development of diabetes of 8.1 
(95% CI, 2.6 to 25.3). The prediabetes definition includes patients with transient and confirmed type 2 diabetes. In Panel C, all patients 
in whom diabetes had developed had prediabetes at screening, except for one patient in the placebo group (indicated by a red circle), 
who had normoglycemia. The numbers along the graphs show the cumulative number of patients who received a diagnosis of diabetes 
over the course of 56 weeks. The numbers of patients at risk (i.e., remaining in the trial) are shown in the table beneath the x axis.
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Event Liraglutide (N = 2481) Placebo (N = 1242)
No. of 
Patients (%) No. of Events
Event Rate per 
100 Exposure- 
Years
No. of 
Patients (%) No. of Events
Event Rate per 
100 Exposure- 
Years
Adverse events in ≥5% of patients 1992 (80.3) 7191 321.8 786 (63.3) 2068 193.7
Nausea 997 (40.2) 1429 63.9 183 (14.7) 223 20.9
Diarrhea 518 (20.9) 754 33.7 115 (9.3) 142 13.3
Constipation 495 (20.0) 593 26.5 108 (8.7) 121 11.3
Vomiting 404 (16.3) 597 26.7 51 (4.1) 62 5.8
Dyspepsia 236 (9.5) 282 12.6 39 (3.1) 44 4.1
Upper abdominal pain 141 (5.7) 171 7.7 43 (3.5) 49 4.6
Abdominal pain 130 (5.2) 163 7.3 43 (3.5) 53 5.0
Nasopharyngitis 427 (17.2) 586 26.2 234 (18.8) 302 28.3
Upper respiratory tract infection 213 (8.6) 247 11.1 122 (9.8) 149 14.0
Sinusitis 128 (5.2) 141 6.3 73 (5.9) 95 8.9
Influenza 144 (5.8) 170 7.6 66 (5.3) 84 7.9
Headache 327 (13.2) 441 19.7 154 (12.4) 220 20.6
Dizziness 167 (6.7) 203 9.1 60 (4.8) 65 6.1
Decreased appetite 267 (10.8) 283 12.7 38 (3.1) 39 3.7
Back pain 171 (6.9) 210 9.4 105 (8.5) 121 11.3
Arthralgia 125 (5.0) 133 6.0 71 (5.7) 80 7.5
Fatigue 185 (7.5) 203 9.1 65 (5.2) 72 6.7
Injection-site hematoma 142 (5.7) 154 6.9 93 (7.5) 101 9.5
Serious adverse events in ≥0.2% of patients 154 (6.2) 194 8.7 62 (5.0) 75 7.0
Cholelithiasis 20 (0.8) 20 0.9 5 (0.4) 5 0.5
Cholecystitis acute 12 (0.5) 12 0.5 0 0 0.0
Osteoarthritis 6 (0.2) 7 0.3 0 0 0.0
Intervertebral disc protrusion 5 (0.2) 5 0.2 1 (0.1) 1 0.1
Pancreatitis acute† 4 (0.2) 4 0.2 0 0 0.0
Cholecystitis 4 (0.2) 4 0.2 0 0 0.0
Breast cancer 4 (0.2) 4 0.2 1 (0.1) 1 0.1
Back pain 2 (0.1) 2 <0.1 2 (0.2) 2 0.2
Uterine leiomyoma 1 (<0.1) 1 <0.1 2 (0.2) 2 0.2
Cellulitis 1 (<0.1) 1 <0.1 3 (0.2) 3 0.3
Gastroesophageal reflux disease 0 0 0.0 2 (0.2) 2 0.2
Bronchitis 0 0 0.0 2 (0.2) 2 0.2
Bladder prolapse 0 0 0.0 2 (0.2) 2 0.2
Chest pain 0 0 0.0 3 (0.2) 3 0.3
*  Adverse events and serious adverse events that occurred up to and including week 58 among patients in the safety-analysis set are included 
and are presented by their preferred terms from the Medical Dictionary for Regulatory Activities. Events are included if they had an onset 
date on or after the first day the study drug was administered and no later than 14 days after the last day the study drug was administered.
†  “Pancreatitis acute” was reported as serious by the investigator but was classified as mild according to revised Atlanta classification of acute 
pancreatitis.19
Table 3. Adverse Events and Serious Adverse Events.*
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group (0.4%; 0.4 events per 100 patient-years at 
risk), of whom 9 had cases graded as mild,19 and 
in 1 of 1242 patients in the placebo group 
(<0.1%; <0.1 events per 100 patient-years at risk). 
Six patients (5 of whom were in the liraglutide 
group) had gallstone-related pancreatitis, which 
was indicated by the presence of gallstones on 
imaging, alanine aminotransferase levels that 
were 3 or more times the upper limit of the nor-
mal range, or both.20 Increases from baseline to 
week 56 in mean lipase and amylase activity 
(12.0 and 3.7 U per liter, respectively) were ob-
served in the liraglutide group, but few patients 
had a lipase value that was 3 or more times the 
upper limit of the normal range (62 of 2447 pa-
tients [2.5%] in the liraglutide group and 13 of 
1220 patients [1.1%] in the placebo group) or an 
amylase value that was 3 or more times the up-
per limit of the normal range (5 of 2447 patients 
[0.2%] in the liraglutide group and 1 of 1220 
patients [<0.1%] in the placebo group) at any 
time during the trial. The positive predictive 
value of isolated enzyme elevations for diagnos-
ing pancreatitis was low (<1% for a lipase value 
≥3 times the upper limit of the normal range; 
there were no amylase values ≥3 times the upper 
limit of the normal range among patients who 
reported pancreatitis).
The mean resting pulse was increased in the 
liraglutide group by the end of the trial (Table 2). 
Additional data on vital signs are provided in the 
Safety Results section in the Supplementary Ap-
pendix. Prespecified cardiovascular events (Table 
S2 in the Supplementary Appendix) occurred in 
217 of 2481 patients in the liraglutide group 
(8.7%; 11.9 events per 100 patient-years of expo-
sure) and in 123 of 1242 patients in the placebo 
group (9.9%; 14.2 events per 100 patient-years of 
exposure). The rates of cardiac arrhythmia were 
similar in the two study groups, although the 
event rate for tachycardia was higher in the lira-
glutide group than in the placebo group (0.6 events 
per 100 patient-years of exposure vs. 0.1 events per 
100 patient-years of exposure; all but 1 event in 
the liraglutide group were nonserious). Two non-
fatal myocardial infarctions and one death from 
cardiovascular causes occurred in the liraglutide 
group, as compared with one nonfatal myocardial 
infarction, one nonfatal stroke, and one death 
from cardiovascular causes in the placebo group.
The incidence of adjudicated and confirmed 
neoplasms was similar in the liraglutide group 
and the placebo group (1.9 per 100 patient-years 
at risk and 2.4 events per 100 patient-years at 
risk, respectively). A numerical imbalance was 
observed in the incidence of malignant and pre-
malignant breast neoplasms: 10 events in nine 
women in the liraglutide group versus 3 events 
in three women in the placebo group. Most 
women with events had above-average weight 
loss (see the Safety Results section in the Sup-
plementary Appendix). There were no cases of 
medullary thyroid carcinoma or C-cell hyperpla-
sia, and liraglutide treatment did not increase 
serum calcitonin concentrations.
No clinically relevant between-group differ-
ences were observed with respect to mental health 
assessments, including adverse events related to 
psychiatric disorders and questionnaire-based de-
pression or suicidal behavior scores (see the Safety 
Results section in the Supplementary Appendix).
Spontaneous hypoglycemia was reported by 
32 of 2481 patients (1.3%) in the liraglutide group 
and by 13 of 1242 patients (1.0%) in the placebo 
group (see the Safety Results section in the Sup-
plementary Appendix); no events were serious or 
required third-party assistance.21
Data on changes in the use of antihyperten-
sive and lipid-lowering medications and addi-
tional safety information are provided in the 
Safety Results section in the Supplementary Ap-
pendix, and results from the second randomized 
period after the end of the 56-week main study 
are shown in Table S19 in the Supplementary 
Appendix. No adverse effects with respect to 
safety variables or cases of binge eating were ob-
served in association with treatment cessation.
Discussion
Liraglutide at a once-daily dose of 3.0 mg, when 
used as an adjunct to a reduced-calorie diet and 
increased physical activity, was associated with 
increased weight loss in overweight and obese 
adults who did not have diabetes, a finding that 
confirms the findings in previous trials.10,11 Lira-
glutide was shown to be superior to placebo 
with respect to all three coprimary end points. 
The treatment effect was similar in patients with 
prediabetes and those without prediabetes and 
was similar across baseline BMI categories. The 
mean change in body weight with liraglutide was 
−8.0±6.7% (−8.4±7.3 kg) and was generally main-
tained over the course of the 56-week main 
study period, as long as the patients continued 
treatment.
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Liraglutide treatment was associated with re-
ductions in cardiometabolic risk factors, includ-
ing waist circumference, blood pressure, and 
inflammatory markers. Modest improvements in 
fasting lipid levels were also observed, although 
the clinical relevance of these improvements is 
uncertain. Furthermore, patients in the liraglu-
tide group had greater reductions in fasting and 
postprandial glycemic variables and more im-
provement with respect to beta-cell function and 
insulin sensitivity than did the placebo group. 
The combination of weight loss and improved 
glycemic control probably contributed to the 
observed reductions in the prevalence of predia-
betes and the delayed onset of type 2 diabetes. 
There were improvements in health-related qual-
ity of life, notably physical function, with lira-
glutide, as compared with placebo.
The safety profile of liraglutide was consistent 
with findings in previous reports.9-11,22,23 Gastro-
intestinal disorders are common and mostly 
transient side effects of treatment.23 Gallbladder-
related events were more common with liraglu-
tide than with placebo; patients with such events 
had above-average weight loss, which is consis-
tent with the known risk of gallstones in asso-
ciation with weight loss.24 Other mechanisms 
may be involved.25 In the current trial, half the 
pancreatitis cases in the liraglutide group were 
associated with gallstones, and elevations of pan-
creatic enzymes were not predictive. The lack of 
a treatment effect on calcitonin concentration 
and the absence of C-cell hyperplasia or medul-
lary thyroid carcinoma events are consistent with 
the prior observation that liraglutide exposure is 
not associated with medullary thyroid carcino-
ma in humans.26 The reason for the numerical 
imbalance in breast neoplasms that we observed 
is unclear; whether there was enhanced ascertain-
ment related to greater weight loss is unknown.
The clinical relevance of increased resting 
pulse with liraglutide is unknown but is proba-
bly related to the drug class.27 The presence of 
glucagon-like peptide-1 receptors on the sino-
atrial node suggests a direct chronotropic effect.28 
No increase in the number of serious cardiovas-
cular events was observed in the liraglutide 
group, and beneficial effects of liraglutide were 
seen with respect to blood pressure and other 
cardiometabolic variables.
Limitations of the trial include the use of last-
observation-carried-forward imputation in the pre-
specified primary analyses.29 However, the robust-
ness of the primary analyses was confirmed in 
sensitivity analyses with the use of alternative 
imputation methods to account for patients who 
withdrew from the trial. Furthermore, no correc-
tion for multiple testing was performed for sec-
ondary end points. Strengths of the trial include 
the large sample size, the independent blinded 
adjudication of specific adverse events, low attri-
tion rates as compared with other weight-loss 
trials,30-32 and a lifestyle intervention with resul-
tant weight loss.
In conclusion, 3.0 mg of once-daily subcuta-
neous liraglutide, as an adjunct to diet and exer-
cise, was associated with clinically meaningful 
weight loss in overweight or obese patients, with 
concurrent reductions in glycemic variables and 
multiple cardiometabolic risk factors, as well as 
improvements in health-related quality of life.
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